Summit Therapeutics Inc
NASDAQ:SMMT

Watchlist Manager
Summit Therapeutics Inc Logo
Summit Therapeutics Inc
NASDAQ:SMMT
Watchlist
Price: 20.16 USD 1.56% Market Closed
Market Cap: 15B USD

Intrinsic Value

There is not enough data to reliably calculate the intrinsic value of SMMT.

The Intrinsic Value is calculated as the average of DCF and Relative values:

SMMT Intrinsic Value
Not Available
Base Case Scenario
Compare SMMT to

Fundamental Analysis

Company Overview
Loading...
Business Segments
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
Bear Theses

Summit's lead antibiotic candidate, ridinilazole, faces heightened regulatory uncertainty after mixed trial data, casting doubt on its commercial viability and threatening the company’s near-term revenue prospects.

Bull Theses

Ridinilazole’s focus on addressing C. difficile infection with a targeted mechanism of action could earn it a first-in-class profile, positioning Summit for significant market share in a vital therapeutic area.

Show More Less
How do you feel about SMMT?
Bearish
Neutral
Bullish
AI Assistant
AI Assistant
Ask me anything about Summit Therapeutics Inc
Financials
Annual
Quarterly
TTM

Balance Sheet Decomposition
Summit Therapeutics Inc

Current Assets 423.8m
Cash & Short-Term Investments 412.3m
Receivables 557k
Other Current Assets 10.8m
Non-Current Assets 11.8m
PP&E 7.4m
Intangibles 1.9m
Other Non-Current Assets 2.5m
Efficiency

Free Cash Flow Analysis
Summit Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Summit Therapeutics Inc

Revenue
0 USD
Operating Expenses
-211m USD
Operating Income
-211m USD
Other Expenses
-10.3m USD
Net Income
-221.3m USD
Fundamental Scores

SMMT Profitability Score
Profitability Due Diligence

Summit Therapeutics Inc's profitability score is 19/100. The higher the profitability score, the more profitable the company is.

19/100
Profitability
Score

Summit Therapeutics Inc's profitability score is 19/100. The higher the profitability score, the more profitable the company is.

SMMT Solvency Score
Solvency Due Diligence

Summit Therapeutics Inc's solvency score is 69/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
69/100
Solvency
Score

Summit Therapeutics Inc's solvency score is 69/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

SMMT Price Targets Summary
Summit Therapeutics Inc

Wall Street analysts forecast SMMT stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for SMMT is 38.12 USD with a low forecast of 30.3 USD and a high forecast of 46.2 USD.

Lowest
Price Target
30.3 USD
50% Upside
Average
Price Target
38.12 USD
89% Upside
Highest
Price Target
46.2 USD
129% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Summit Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for SMMT is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

SMMT Insider Trading
Buy and sell transactions by insiders

SMMT News

Other Videos